University of Hull
66
5
11
35
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 75/100
16.7%
11 terminated/withdrawn out of 66 trials
76.1%
-10.4% vs industry average
6%
4 trials in Phase 3/4
14%
5 of 35 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (66)
Tumour Regulatory Molecules in Early Pancreatic Cancer Detection
Role: collaborator
Exercise for Improving Radiotherapy Efficacy in Rectal Cancer
Role: lead
DACC in the REduction of Surgical Site INfection
Role: collaborator
Improving Uptake of Bowel Cancer Screening Among South Asian Adults in Bradford
Role: lead
Facilitating Effective Eating With DoddleBags: A Single-Arm Acceptability Study Of DoddleBags to Assess Impact on Self Feeding Behaviours in a Huntington's Disease Population
Role: lead
Clinical and Cost Effectiveness of ACE Inhibitor, Ramipril, in Intermittent Claudicants
Role: collaborator
HbA1c Variability in Type II Diabetes
Role: collaborator
Extracorporeal Shockwave Therapy for Diabetic Foot Wounds
Role: collaborator
Exercise for Improving Long-course Chemoradiotherapy Efficacy in People With Locally Advanced Rectal Cancer
Role: lead
Shockwave Therapy in Lower Limb Intermittent Calf Claudication
Role: collaborator
FreeStyle Libre Monitoring in T2DM
Role: lead
CD8 Minibody Repeatability Study
Role: collaborator
High Intensity Interval Training In pATiEnts With Intermittent Claudication
Role: collaborator
Acceptability of an Interim Socket System
Role: lead
Exercise for Ameliorating Chemotherapy Cardiotoxicity
Role: lead
Prehabilitation and RecOVERy From Surgery for Breast Cancer Study
Role: collaborator
HCV Microfluidic Diagnostics
Role: lead
BoneFit: Multimodal Prehabilitation for People Preparing for Orthopaedic Surgery
Role: lead
Improving Wellbeing and Health for Care Home Residents During COVID-19
Role: collaborator
Semaglutide vs Metformin in Polycystic Ovary Syndrome (PCOS)
Role: lead